Trimetazidine-Biocom MV
Trimetazidin-Biocom MV: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Drug interactions
- 14. Analogs
- 15. Terms and conditions of storage
- 16. Terms of dispensing from pharmacies
- 17. Reviews
- 18. Price in pharmacies
Latin name: Trimetazidine-Biokom MR
ATX code: C01EB15
Active ingredient: Trimetazidine (Trimetazidine)
Producer: BIOCOM, CJSC (Russia)
Description and photo update: 2018-25-10
Prices in pharmacies: from 129 rubles.
Buy
Trimetazidine-Biocom MB is an antihypoxant drug with antianginal action.
Release form and composition
Dosage form of the drug Trimetazidin-Biocom MV - modified release coated tablets: pink, round, biconvex (in a blister contour packaging made of aluminum foil and PVC film, 10 pcs., In a cardboard box, 1, 2, 3, 4, 5 or 6 packs).
Composition of 1 tablet:
- active substance: trimetazidine dihydrochloride - 35 mg;
- auxiliary components (core): calcium hydrogen phosphate dihydrate, povidone (medical low molecular weight polyvinylpyrrolidone), hypromellose (hydroxypropyl methylcellulose 4000), magnesium stearate, aerosil (colloidal silicon dioxide);
- shell: macrogol (polyethylene glycol 6000), hypromellose (hydroxypropyl methylcellulose 4000), titanium dioxide, red iron oxide dye.
Pharmacological properties
Pharmacodynamics
Trimetazidine dihydrochloride has antihypoxic and antianginal effects. The active substance, by directly affecting the neurons of the brain and cardiomyocytes (muscle cells of the heart), optimizes their construction and functioning. Due to the increase in energy potential, activation of the biochemical process of oxidative decarboxylation and rationalization of oxygen consumption (by enhancing the reactions of aerobic glycolysis and blockade of fatty acid oxidation), a cytoprotective effect takes place.
Trimetazidine stimulates myocardial contractility, prevents a decrease in the intracellular content of adenosine triphosphoric acid (ATP) and phosphocreatinine, improves the activity of ion channels in acidosis, prevents the accumulation of sodium and calcium in cardiomyocytes, and normalizes the concentration of potassium ions in the muscle cells of the heart. Trimetazidine reduces the concentration of phosphates and the amount of intracellular acidosis caused by reperfusion and myocardial ischemia.
In addition, the drug inhibits the damaging effect of free radicals, helps to preserve the integrity of cell membranes, in the ischemic zone prevents the activation of neutrophils, reduces the release of the enzyme creatine phosphokinase from the cells and the manifestation of ischemic damage to the myocardium, and also affects the increase in the duration of the electric potential.
Trimetazidine reduces the frequency of angina attacks (due to a decrease in nitrate consumption). Approximately two weeks after the start of therapy, changes in blood pressure (blood pressure) decrease, exercise tolerance increases, the results of vestibular tests normalize, hearing is restored, tinnitus and dizziness decrease.
The drug helps to restore the functional activity of the retina in vascular diseases of the eyes.
Pharmacokinetics
After oral administration, trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability is 90%. After a single dose of 35 mg of trimetazidine dihydrochloride, the maximum plasma concentration is approximately 55 ng / ml, the time to reach it is 2 hours. The substance tends to easily penetrate the histohematogenous barriers. 16% of the drug binds to plasma proteins. It is excreted by the kidneys (unchanged about 60%). T 1/2 (half-life) is 4.5-5 hours.
Indications for use
- ischemic heart disease - in complex therapy for the prevention of angina attacks;
- dizziness due to vascular diseases;
- chorioretinal vascular disorders;
- cochleovestibular disorders of ischemic origin (including hearing impairment, tinnitus).
Contraindications
- severe renal dysfunction (creatinine clearance less than 15 ml / min);
- severe liver dysfunction;
- pregnancy and lactation;
- age up to 18 years;
- individual hypersensitivity to trimetazidine or any auxiliary component of the drug.
Instructions for use of Trimetazidin-Biocom MV: method and dosage
Trimetazidine-Biocom MB is taken orally, during meals.
Recommended dosage: 2 tablets (70 mg) 2 times a day; the duration of the course of treatment is determined by the doctor.
Side effects
When taking the drug Trimetazidin-Biocom MB, allergic reactions in the form of itching may occur.
In rare cases, the appearance of a headache, a feeling of a strong heartbeat, and from the gastrointestinal tract - nausea, vomiting, pain in the stomach.
Overdose
There is no information on drug overdose at this time.
special instructions
Trimetazidine-Biocom MV cannot be used to relieve angina attacks.
In patients with ischemic heart disease, the daily requirement for nitrates is significantly reduced during therapy with the drug.
Influence on the ability to drive vehicles and complex mechanisms
Taking the drug does not affect the ability to perform work associated with an increased risk of accidents, including driving vehicles.
Application during pregnancy and lactation
According to the instructions, Trimetazidin-Biocom MV is contraindicated for use in women during pregnancy and breastfeeding.
Pediatric use
Since there is no information on the efficacy and safety of the drug in children and adolescents under 18 years of age, it is not recommended to use Trimetazidine-Biocom MV in this category of patients.
With impaired renal function
In patients with severe renal insufficiency (with creatinine clearance less than 15 ml / min), the use of Trimetazidine-Biocom MV is contraindicated.
For violations of liver function
The drug should not be administered to patients with severe liver dysfunction.
Drug interactions
There is no information on the interaction of trimetazidine with other medicinal substances.
Analogs
Analogs of Trimetazidin-Biocom MV are: Angiosil retard, Antisten, Vero-Trimetazidin, Deprenorm MV, Predizin, Preductal MV, Rimecor, Triducard, Trimectal MV, Trimetazidin MV, Trimetazidin-Teva, Trimitard MV and others.
Terms and conditions of storage
Store in a dark, dry place at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Trimetazidine-Biocom MV
In the reviews, Trimetazidin-Biocom MV is characterized positively. The tablets help with dizziness, tinnitus, hearing impairment.
The drug is in demand due to its low cost compared to imported similar drugs.
Price for Trimetazidine-Biocom MB in pharmacies
The price for Trimetazidin-Biocom MB for one package is approximately: 30 tablets - from 128 to 175 rubles, 60 tablets - from 170 to 225 rubles.
Trimetazidine-Biocom MV: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Trimetazidin-Biocom MV 35 mg coated tablets with modified release 30 pcs. 129 RUB Buy |
|
Trimetazidin-Biocom MB tablets p.p. 35mg 30 Pcs. RUB 150 Buy |
|
Trimetazidin-Biocom MV 35 mg coated tablets with modified release 60 pcs. 162 RUB Buy |
|
Trimetazidin-Biocom MV tablets p.p. 35mg 60 Pcs. 203 r Buy |
|
Trimetazidin-Biocom MV 35 mg coated tablets with modified release 120 pcs. 387 r Buy |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
